Popular
ABVX · Medicine & biotech · France

Abivax

Develops a pill for ulcerative colitis, a painful gut disease.

Company Health

33
/100
Weak
A quick check of the business from its yearly reports (2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It doesn’t sell much yet, and it lost money last year.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in last year.

Who owns it

2 of 23 own it · 2 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Abivax’s yearly reports, in euros. Tap a year to see its figures.

Sales and profit

It lost money every year.
2025
Loss
€336 million

Spare cash each year

It spent more cash than it brought in every year: €161 million more in 2025.
2025
Cash shortfall
€161 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned €584 million, including €517 million in cash, and owed €129 million.

Key facts

From its yearly report for 2025.
Loss
€336 million
Cash shortfall
€161 million
Cash in the bank
€517 million
Everything it owes
€129 million
Year ends
December
Money shown in
Euros
Latest yearly report
20-F, filed Mar 23, 2026
Figures from Abivax’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy